Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Reply

• Type of Material: Article
• Authors: BK Titanji, Emory University; Monica Farley, Emory University; Raymond Schinazi, Emory University; Vincent Marconi, Emory University
• Language: English
• Date: 2021-12-01
• Publisher: Oxford University Press Inc.
• Publication Version: Final Published Version
• Copyright Statement: © Published by Oxford University Press for the Infectious Diseases Society of America 2020.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/cid/ciaa1210
• Title of Journal or Parent Work: Clinical Infectious Diseases
• Volume: 73
• Issue: 11
• Start Page: E3980
• End Page: E3981
• Grant/Funding Information: V. M. and R. F. S. are partially funded by—Emory University Center for AIDS Research (AI050409). R. F. S. is funded in part by National Institutes of Health (NIH) grant 5-R01-MH116695.
• Keywords: Infectious Diseases; Life Sciences & Biomedicine; Microbiology; Immunology; Science & Technology
• Research Categories: Biology, Microbiology; Health Sciences, Epidemiology; Health Sciences, Immunology; Health Sciences, Public Health

Abstract

to the editor—We read with interest the correspondence by Jorgensen et al in response to our recent publication in Clinical Infectious Diseases on the use of baricitinib for treatment of patients with moderate to severe coronavirus disease 2019 (COVID-19). The authors raise concerns on the potential impact of Janus kinase (JAK) inhibitors on COVID-19 coagulopathy, citing data on tofacitinib and baricitinib from the World Health Organization (WHO) Vigibase [1].